{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:26:10Z","timestamp":1787268370007,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Startup Fund for Scientific Research at Fujian Medical University","award":["2019QH1272"],"award-info":[{"award-number":["2019QH1272"]}]},{"name":"the Natural Science Foundation of Fujian Province","award":["2020J011304"],"award-info":[{"award-number":["2020J011304"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-57074-4","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:08:15Z","timestamp":1781021295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["LncRNA IRAIN inhibits mantle cell lymphoma progression by inducing cell cycle arrest and apoptosis: an in vitro study"],"prefix":"10.1038","volume":"16","author":[{"given":"Ping","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"57074_CR1","doi-asserted-by":"publisher","first-page":"e70009","DOI":"10.1002\/hon.70009","volume":"43","author":"D Albano","year":"2025","unstructured":"Albano, D. et al. Prognostic role of pretreatment tumor burden and dissemination features from 2-[(18)F]FDG PET\/CT in advanced mantle cell lymphoma. Hematol. Oncol. 43, e70009 (2025).","journal-title":"Hematol. Oncol."},{"key":"57074_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13000-024-01577-z","volume":"19","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Clinical significance of Cyclin D1 by complete quantification detection in mantle cell lymphoma: positive indicator in prognosis. Diagn. Pathol. 19, 149 (2024).","journal-title":"Diagn. Pathol."},{"key":"57074_CR3","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1038\/s41375-024-02375-8","volume":"38","author":"M Khouja","year":"2024","unstructured":"Khouja, M. et al. Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle cell lymphoma: Results from the EU-MCL network trials. Leukemia 38, 3675 (2024).","journal-title":"Leukemia"},{"key":"57074_CR4","doi-asserted-by":"publisher","first-page":"7298","DOI":"10.3390\/ijms25137298","volume":"25","author":"G Orfanoudaki","year":"2024","unstructured":"Orfanoudaki, G., Psatha, K. & Aivaliotis, M. Insight into Mantle cell lymphoma pathobiology, diagnosis, and treatment using network-based and drug-repurposing approaches. Int. J. Mol. Sci. 25, 7298 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"57074_CR5","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMra2202672","volume":"386","author":"JO Armitage","year":"2022","unstructured":"Armitage, J. O. & Longo, D. L. Mantle-cell lymphoma. N. Engl. J. Med. 386, 2495 (2022).","journal-title":"N. Engl. J. Med."},{"key":"57074_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s44313-024-00037-3","volume":"59","author":"X He","year":"2024","unstructured":"He, X. et al. Prognostic significance and biological implications of SM-like genes in mantle cell lymphoma. Blood Res. 59, 33 (2024).","journal-title":"Blood Res."},{"key":"57074_CR7","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s11912-022-01297-x","volume":"24","author":"M Tarockoff","year":"2022","unstructured":"Tarockoff, M., Gonzalez, T., Ivanov, S. & Sandoval-Sus, J. Mantle cell lymphoma: The role of risk-adapted therapy and treatment of relapsed disease. Curr. Oncol. Rep. 24, 1313 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"57074_CR8","first-page":"12268","volume":"8","author":"J Feng","year":"2015","unstructured":"Feng, J. et al. A novel long noncoding RNA IRAIN regulates cell proliferation in non small cell lung cancer. Int. J. Clin. Exp. Pathol. 8, 12268 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"57074_CR9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.immuni.2015.05.004","volume":"42","author":"AT Satpathy","year":"2015","unstructured":"Satpathy, A. T. & Chang, H. Y. Long noncoding RNA in hematopoiesis and immunity. Immunity 42, 792 (2015).","journal-title":"Immunity"},{"key":"57074_CR10","doi-asserted-by":"publisher","first-page":"18534","DOI":"10.18632\/oncotarget.4069","volume":"6","author":"JM Hughes","year":"2015","unstructured":"Hughes, J. M. et al. C\/EBP\u03b1-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia. Oncotarget 6, 18534 (2015).","journal-title":"Oncotarget"},{"key":"57074_CR11","first-page":"6787","volume":"18","author":"Y Jiang","year":"2019","unstructured":"Jiang, Y., Chen, J. & Chen, G. Long noncoding RNA IRAIN acts as tumor suppressor via miR-125b in multiple myeloma. Oncol. Lett. 18, 6787 (2019).","journal-title":"Oncol. Lett."},{"key":"57074_CR12","first-page":"543","volume":"37","author":"A Guo","year":"2022","unstructured":"Guo, A. et al. Overexpression of lncRNA IRAIN restrains the progression and Temozolomide resistance of glioma via repressing IGF-1R-PI3K-NF-kappaB signaling pathway. Histol. Histopathol. 37, 543 (2022).","journal-title":"Histol. Histopathol."},{"key":"57074_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.031","author":"L Kang","year":"2015","unstructured":"Kang, L. et al. Aberrant allele-switch imprinting of a novel IGF1R intragenic antisense non-coding RNA in breast cancers. Eur J Cancer https:\/\/doi.org\/10.1016\/j.ejca.2014.10.031 (2015).","journal-title":"Eur J Cancer"},{"key":"57074_CR14","first-page":"1","volume":"20","author":"JY Wang","year":"2020","unstructured":"Wang, J. Y., Liu, D., Di Meng, Y., Guo, Y. Y. & Zhao, M. Aberrant allelic-switch of antisense lncRNA IRAIN may be an early diagnostic marker in laryngeal cancer. Oncol. Lett. 20, 1 (2020).","journal-title":"Oncol. Lett."},{"key":"57074_CR15","doi-asserted-by":"publisher","DOI":"10.1515\/biol-2016-0026","author":"W Zhiqiang","year":"2016","unstructured":"Zhiqiang, W. et al. Abnormal expressed long non-coding RNA IRAIN inhibits tumor progression in human renal cell carcinoma cells. Open Life Sci. https:\/\/doi.org\/10.1515\/biol-2016-0026 (2016).","journal-title":"Open Life Sci."},{"key":"57074_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.12.012","author":"Y Shi","year":"2004","unstructured":"Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell https:\/\/doi.org\/10.1016\/j.cell.2004.12.012 (2004).","journal-title":"Cell"},{"key":"57074_CR17","doi-asserted-by":"publisher","first-page":"ziae142","DOI":"10.1093\/jbmrpl\/ziae142","volume":"9","author":"K Astleford-Hopper","year":"2025","unstructured":"Astleford-Hopper, K., Abrahante Llorens, J. E., Bradley, E. W. & Mansky, K. C. Lysine specific demethylase 1 conditional myeloid cell knockout mice have decreased osteoclast differentiation due to increased IFN-beta gene expression. JBMR Plus 9, ziae142 (2025).","journal-title":"JBMR Plus"},{"key":"57074_CR18","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01524","author":"HJ Zhu","year":"2024","unstructured":"Zhu, H. J. et al. Discovery of novel 5-cyano-3-phenylindole-based LSD1\/HDAC dual inhibitors for colorectal cancer treatment. J. Med. Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01524 (2024).","journal-title":"J. Med. Chem."},{"key":"57074_CR19","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2017.3032","author":"ZK Zou","year":"2017","unstructured":"Zou, Z. K., Huang, Y. Q., Zou, Y., Zheng, X. K. & Ma,. Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeKo-1 and MOLT-4 cells. Int. J. Mol. Med. https:\/\/doi.org\/10.3892\/ijmm.2017.3032 (2017).","journal-title":"Int. J. Mol. Med."},{"key":"57074_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00847-8","author":"K Shinjo","year":"2024","unstructured":"Shinjo, K. et al. Novel pharmacologic inhibition of lysine-specific demethylase 1 as a potential therapeutic for glioblastoma. Cancer Gene Ther. https:\/\/doi.org\/10.1038\/s41417-024-00847-8 (2024).","journal-title":"Cancer Gene Ther."},{"key":"57074_CR21","doi-asserted-by":"publisher","first-page":"22080","DOI":"10.1021\/acs.jmedchem.4c02017","volume":"67","author":"H Jiang","year":"2024","unstructured":"Jiang, H. et al. Optimization and biological evaluation of novel 1H-Pyrrolo[2,3-c]pyridin derivatives as potent and reversible lysine specific demethylase 1 inhibitors for the treatment of acute myelogenous leukemia. J. Med. Chem. 67, 22080 (2024).","journal-title":"J. Med. Chem."},{"key":"57074_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3892\/ol.2020.12354","volume":"21","author":"M Wang","year":"2021","unstructured":"Wang, M., Liu, X., Chen, Z., Zhang, L. & Weng, X. Downregulation of lysine-specific demethylase 1 enhances the sensitivity of hormone-sensitive prostate cancer cells to androgen deprivation therapy. Oncol. Lett. 21, 93 (2021).","journal-title":"Oncol. Lett."},{"key":"57074_CR23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.gendis.2022.11.002","volume":"10","author":"P He","year":"2023","unstructured":"He, P. et al. Inhibition of lysine-specific demethylase 1 (LSD1) prevented tumor growth and metastasis by downregulating PD-L1 expression in lung adenocarcinoma. Genes Dis. 10, 1779 (2023).","journal-title":"Genes Dis."},{"key":"57074_CR24","doi-asserted-by":"publisher","first-page":"7054","DOI":"10.7150\/thno.102037","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Unlocking the dual role of LSD1 in tumor immunity: innate and adaptive pathways. Theranostics 14, 7054 (2024).","journal-title":"Theranostics"},{"key":"57074_CR25","doi-asserted-by":"publisher","first-page":"16165","DOI":"10.1021\/acs.jmedchem.4c00972","volume":"67","author":"B Wang","year":"2024","unstructured":"Wang, B. et al. Discovery of 2-Aryl-4-aminoquinazolin-based LSD1 inhibitors to activate immune response in gastric cancer. J. Med. Chem. 67, 16165 (2024).","journal-title":"J. Med. Chem."},{"key":"57074_CR26","doi-asserted-by":"publisher","first-page":"14929","DOI":"10.1007\/s13277-016-5380-8","volume":"37","author":"Y Lian","year":"2016","unstructured":"Lian, Y. et al. Long non-coding RNA IRAIN suppresses apoptosis and promotes proliferation by binding to LSD1 and EZH2 in pancreatic cancer. Tumour Biol. 37, 14929 (2016).","journal-title":"Tumour Biol."},{"key":"57074_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12032-024-02453-y","volume":"41","author":"R Kharrat","year":"2024","unstructured":"Kharrat, R. et al. Anticancer effects of Artemisia campestris extract on acute myeloid leukemia cells: an ex vivo study. Med. Oncol. 41, 206 (2024).","journal-title":"Med. Oncol."},{"key":"57074_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/hemato6030030","volume":"6","author":"M Abdelkarim","year":"2025","unstructured":"Abdelkarim, M. et al. miR-429 acts as a tumor suppressor in multiple myeloma by regulating cell proliferation. Hemato 6, 30 (2025).","journal-title":"Hemato"},{"key":"57074_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40164-020-00182-2","volume":"9","author":"L Lin","year":"2020","unstructured":"Lin, L., Huang, Y., Zhuang, W., Lin, P. & Ma, X. miR-100 inhibits cell proliferation in mantle cell lymphoma by targeting mTOR. Exp. Hematol. Oncol. 9, 25 (2020).","journal-title":"Exp. Hematol. Oncol."},{"key":"57074_CR30","doi-asserted-by":"publisher","first-page":"37753","DOI":"10.18632\/oncotarget.26514","volume":"9","author":"A Padgaonkar","year":"2018","unstructured":"Padgaonkar, A. et al. Targeting protein kinase CK2 and CDK4\/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia. Oncotarget 9, 37753 (2018).","journal-title":"Oncotarget"},{"key":"57074_CR31","doi-asserted-by":"publisher","first-page":"0289902","DOI":"10.1371\/journal.pone.0289902","volume":"19","author":"I Bijou","year":"2024","unstructured":"Bijou, I. et al. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLoS ONE 19, 0289902 (2024).","journal-title":"PLoS ONE"},{"key":"57074_CR32","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.3390\/cells11213394","volume":"11","author":"E Esmeray Sonmez","year":"2022","unstructured":"Esmeray Sonmez, E. et al. Whole transcriptome sequencing reveals cancer-related, prognostically significant transcripts and tumor-infiltrating immunocytes in mantle cell lymphoma. Cells 11, 3394 (2022).","journal-title":"Cells"},{"key":"57074_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.026","author":"S Ren","year":"2013","unstructured":"Ren, S. et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur. J. Cancer https:\/\/doi.org\/10.1016\/j.ejca.2013.04.026 (2013).","journal-title":"Eur. J. Cancer"},{"key":"57074_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103214","author":"X Zhang","year":"2019","unstructured":"Zhang, X., Hong, R., Chen, W., Xu, M. & Wang,. The role of long noncoding RNA in major human disease. Bioorg. Chem. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103214 (2019).","journal-title":"Bioorg. Chem."},{"key":"57074_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179490","author":"O Kersy","year":"2021","unstructured":"Kersy, O., Salmon-Divon, M., Shpilberg, O. & Hershkovitz-Rokah,. Non-coding RNAs in normal B-cell development and in mantle cell lymphoma: From molecular mechanism to biomarker and therapeutic agent potential. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22179490 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"57074_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2018.04.013","author":"L Pian","year":"2018","unstructured":"Pian, L. et al. Targeting the IGF1R Pathway in breast cancer using antisense lncRNA-mediated promoter cis competition. Mol. Ther. Nucleic Acids https:\/\/doi.org\/10.1016\/j.omtn.2018.04.013 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"57074_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku549","author":"J Sun","year":"2014","unstructured":"Sun, J. et al. A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gku549 (2014).","journal-title":"Nucleic Acids Res."},{"key":"57074_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01082","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Long non-coding RNA IRAIN inhibits VEGFA expression via enhancing Its DNA methylation leading to tumor suppression in renal carcinoma. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.01082 (2020).","journal-title":"Front. Oncol."},{"key":"57074_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400450","author":"J Seitz","year":"2024","unstructured":"Seitz, J. et al. Soft drug inhibitors for the epigenetic targets lysine-specific demethylase 1 and histone deacetylases. Arch Pharm (Weinheim) https:\/\/doi.org\/10.1002\/ardp.202400450 (2024).","journal-title":"Arch Pharm (Weinheim)"},{"key":"57074_CR40","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02133","author":"L Shen","year":"2024","unstructured":"Shen, L. et al. Combination therapy and dual-target inhibitors based on LSD1: New emerging tools in cancer therapy. J. Med. Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02133 (2024).","journal-title":"J. Med. Chem."},{"key":"57074_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020164","author":"DY Lee","year":"2023","unstructured":"Lee, D. Y., Salahuddin, T. & Iqbal, J. Lysine-specific demethylase 1 (LSD1)-mediated epigenetic modification of immunogenicity and immunomodulatory effects in breast cancers. Curr. Oncol. https:\/\/doi.org\/10.3390\/curroncol30020164 (2023).","journal-title":"Curr. Oncol."},{"key":"57074_CR42","doi-asserted-by":"publisher","first-page":"5512524","DOI":"10.1155\/2021\/5512524","volume":"2021","author":"C Agboyibor","year":"2021","unstructured":"Agboyibor, C. et al. LSD1 as a biomarker and the outcome of its inhibitors in the clinical trial: The therapy opportunity in tumor. J. Oncol. 2021, 5512524 (2021).","journal-title":"J. Oncol."},{"key":"57074_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29020550","author":"D Han","year":"2024","unstructured":"Han, D. et al. Lysine-specific demethylase 1 inhibitors: A comprehensive review utilizing computer-aided drug design technologies. Molecules https:\/\/doi.org\/10.3390\/molecules29020550 (2024).","journal-title":"Molecules"},{"key":"57074_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030324","author":"B Majello","year":"2019","unstructured":"Majello, B., Gorini, F., Sacca, C. D. & Amente,. Expanding the role of the histone lysine-specific demethylase LSD1 in cancer. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11030324 (2019).","journal-title":"Cancers (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57074-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:14:11Z","timestamp":1787267651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57074-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57074"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57074-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Normal human lymphocytes were isolated from peripheral blood samples of healthy volunteers, all of whom provided informed consent. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Medical Ethics Committee of Zhangzhou Hospital, Fujian Province (Ethical Approval No. 20200315).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26255"}}